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Objective: This study evaluated 1-year safety and effectiveness outcomes of the United States regulatory trial for the
Ovation Abdominal Stent Graft System (TriVascular Inc, Santa Rosa, Calif) for endovascular repair of abdominal aortic
aneurysms (AAAs).
Methods: This prospective, multicenter, single-arm trial was conducted at 36 sites in the United States, Germany, and
Chile to evaluate the safety and effectiveness of the Ovation stent graft. From November 2009 to May 2011, 161 patients
(88% males; mean age, 73 6 8 years) with AAAs (mean diameter, 54 6 9 mm) were treated with the Ovation stent graft.
The main body is a modular two-docking limb device with a 14F outer diameter delivery system, active suprarenal
ﬁxation, and polymer-ﬁlled proximal rings that accommodate the aortic neck for seal. Main inclusion criteria included
proximal aortic neck length $7 mm, inner neck diameter between 16 and 30 mm, distal iliac landing zones length
$10 mm, and diameter between 8 and 20 mm. Patients were treated under a common protocol, including clinical and
imaging follow-up at discharge, 30 days, 6 months, and annually through 5 years. A Clinical Events Committee adju-
dicated adverse events, an independent imaging core laboratory analyzed imaging, and a Data Safety and Monitoring
Board provided study oversight. Complete 1-year follow-up data were available for this report.
Results: The Ovation stent graft was implanted successfully in 161 patients (100%), including 69 (42.9%) by percutaneous
access. General anesthesia was used in 106 patients (65.8%). Technical success was 100%, and mean procedure time was
110 minutes. Median procedural blood loss was 150 mL, and median hospital stay was 1 day. The 30-day major adverse
event rate was 2.5%. At 1 year, AAA-related and all-cause mortality were 0.6% and 2.5%, respectively. Major adverse event
and serious adverse event rates through 1 year were 6.2% and 38.5%, respectively. The 1-year treatment success rate was
99.3%. The imaging core laboratory reported no stent graft migration or type I, III, or IV endoleaks. At 1 year, type II
endoleaks were identiﬁed in 34% of patients, and AAA enlargement was identiﬁed in one patient (0.7%). No AAA rupture
or conversion to open surgery was reported. AAA-related secondary procedures were performed in 10 patients (6.2%) for
12 ﬁndings, including endoleak (six), aortic main body stenosis (three), and iliac limb stenosis or occlusion (three).
Conclusions: The 1-year results of the Ovation Abdominal Stent Graft System demonstrate excellent safety and effec-
tiveness in treatment of patients with AAAs, particularly in patients with challenging anatomic characteristics, including
short aortic necks and narrow iliac arteries. Longer-term follow-up is needed. (J Vasc Surg 2014;59:65-73.)4Endovascular aneurysm repair (EVAR) reduces rupture
risk and results in lower postoperative mortality and
morbidity rates as well as a shorter convalescence compared
with open surgical repair.1-3 Consequently, EVAR has
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aortoiliac anatomy such as short and complex proximal
aortic neck seal zones and narrow access vessels.11-17
Furthermore, late complications after EVAR, including
stent graft migration and loss of seal at the proximal aortic
neck, remain a concern, particularly those that mandate
secondary interventions or conversion to open repair.
Hence, there remains a clinical need for continued
advances in stent graft technology that can accommodate
a wider range of aortoiliac morphology and offer a durable
solution to AAA exclusion.
The Ovation Abdominal Stent Graft System (TriVascu-
lar Inc, Santa Rosa, Calif) is a new device that is designed to
overcome the limitations of currently available stent grafts
and can accommodate a broad range of aortoiliac charac-
teristics, navigate through complex iliac and femoral access,
and provide a seal in complex proximal infrarenal aortic
neck morphology. The purpose of this prospective, interna-
tional, multicenter clinical study was to evaluate the safety
and effectiveness of the Ovation stent graft for treatment
of AAA.
METHODS
Ethics. All research procedures performed in this study
were in strict accordance with a common, predeﬁned
protocol that was prospectively registered at Clinical
Trials.gov as NCT01092117 (U.S.), NCT01097772
(Germany), and NCT01082185 (Chile). The investiga-
tional protocol and informed consent form were approved
by an Institutional Review Board or Ethics Committee,
and all study participants gave written informed consent
before study participation.
Patients. This prospective, single-arm, multicenter
trial enrolled 161 patients from 36 sites in the U.S.,
Germany, and Chile (Supplementary Table I, online only).
Patients underwent elective treatment with the Ovation
stent graft between November 2009 and May 2011.
Eligible patients presented with an AAA requiring inter-
vention, were candidates for open surgery, and had aor-
toiliac characteristics suitable for treatment with the
Ovation stent graft. The primary entry criteria included:
d A proximal neck length of $7 mm and an inner diam-
eter of between 16 and 30 mm;
d A juxtarenal aortic neck angulation of #60 if the
proximal neck length was $10 mm or #45 if the
proximal neck length was <10 mm;
d A distal seal zone of $10 mm and diameter between 8
and 20 mm; and
d An AAA diameter of $5.0 cm, 1.5 times the adjacent
nonaneurysmal aorta, or expansion of $0.5 cm in the
previous 6 months.
Complete inclusion and exclusion criteria are presented
in Supplementary Table II (online only).
Preprocedural evaluation. Participants were con-
secutively evaluated for study eligibility. Patients who
met all study entry criteria were evaluated for demographicinformation and medical history and underwent a physical
examination, laboratory testing, and contrast-enhanced
spiral abdominal/pelvic computed tomography (CT)
imaging.
Device description. The Ovation stent graft was
designed to overcome the limitations of previous stent
grafts by accommodating a broader range of aortoiliac
anatomy with a low-proﬁle 14F outer diameter (OD)
delivery system and a proximal aortic neck seal mechanism
designed to conform to and accommodate the aortic neck.
The Ovation stent graft is characterized by a trimodular
design, with the aortic body delivered by a ﬂexible
hydrophilic-coated 14F OD catheter, the smallest proﬁle of
any currently commercially available stent graft (Fig 1).
The aortic body consists of a low-permeability polytetra-
ﬂuoroethylene (PTFE) graft and a suprarenal nitinol stent
with integral anchors to achieve active ﬁxation to the
aortic wall.
The aortic body contains a network of inﬂatable chan-
nels and sealing rings that are ﬁlled during deployment
with a low-viscosity, radiopaque ﬁll polymer that cures in
situ to create a conformable seal to the patient’s aortic
neck. The Ovation iliac limbs consist of highly ﬂexible
nitinol stents encapsulated in low-permeability PTFE that
are packaged in low-proﬁle 13F to 14F OD delivery
systems. Examples of typical pre-to-post radiographic
ﬁndings with the Ovation stent graft are provided in
Figs 2 and 3.
Procedure. The EVAR procedure steps include
femoral artery cutdown or percutaneous approach. Both
techniques were left up to the discretion of the operator.
Subsequent to bilateral femoral access, the trimodular stent
graft is delivered and deployed from the ipsilateral side in
three stages, which include unsheathing the main body,
deploying the suprarenal bare-metal stent, and engaging
the polymer, which is prepared on the back table and
engaged through an automated plunger and exerts 1
atmosphere of pressure to be delivered into and expand
the stent graft main body rings that subsequently conform
to the aortic neck. The iliac rings along the main body
provide support for the ipsilateral and contralateral iliac
extensions.
Follow-up schedule. Patients were monitored through
hospital discharge and returned for follow-up visits at
1 month, 6 months, and annually thereafter through 5 years.
At each visit, patients underwent a physical examination,
laboratory testing, contrast-enhanced spiral abdominal/
pelvic CT (not performed at discharge), and four-view X ray
imaging.
Outcomes. Safety outcomes included Clinical Events
Committee (CEC) adjudicated major adverse events
(MAEs), serious adverse events (SAEs), and mortality
(all-cause and AAA-related). The primary safety end
point was the incidence of MAEs through 30 days, deﬁned
as death, myocardial infarction, stroke, renal failure, respi-
ratory failure, paraplegia, bowel ischemia, or procedural
blood loss $1000 mL. AAA-related mortality was deﬁned
as death due to AAA rupture, due to any procedure
Fig 2. (a), Preoperative angiogram shows the aneurysm and (b) a postoperative angiogram demonstrates successful
aneurysm exclusion with the Ovation Abdominal Stent Graft System.
Fig 1. The Ovation Abdominal Stent Graft System: (a) image of deployed device and (b) schematic of deployed device
with key design characteristics labeled.
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intended to treat the AAA, or any in-hospital death if
hospitalization was >30 days. An SAE was deﬁned as any
event that was fatal, life-threatening, required prolonged
hospitalization (>48 hours), was a persistent or signiﬁcant
disability or incapacity, or was considered an important
medical event.Measures of device effectiveness included technical
success (successful delivery and deployment of the aortic
body and both iliac limbs), imaging core laboratory assess-
ments of endoleak, stent graft migration, AAA enlargement,
and stent fracture, as well as site-reported assessments of
aortic main body stenosis, AAA rupture, AAA-related
secondary intervention, and conversion to open surgery.
Fig 3. A computed tomography (CT) reconstruction shows the aneurysm (a) preoperatively and (b) demonstrates at
1 year successful aneurysm exclusion with the Ovation Abdominal Stent Graft System in a patient with challenging
anatomy. Aortoiliac characteristics include proximal neck length of 7 mm with thrombus, juxtarenal angulation of 49,
and access vessel diameter of 3.9 mm (left) and 4.9 mm (right).
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of patients who experienced treatment success at 1 year,
which was deﬁned as technical success and freedom from
all of the following: type I and III endoleak at 1 year, stent
graft migration (deﬁned as evidence of proximal or distal
movement of the stent graft >10 mm relative to ﬁxed
anatomic landmarks compared with the 1-month CT
scan) at 1 year, and AAA enlargement at 1 year (deﬁned
as a >5-mm AAA diameter increase compared with the
AAA diameter on the 1-month CT scan), all as conﬁrmed
by the core imaging laboratory; AAA rupture through
1 year; and conversion to open surgery through 1 year.
Data quality. All research procedures followed
a common protocol, and each site received thorough and
consistent device and protocol training. All data were
recorded on case report forms using an electronic data
capture system (Phase Forward Inc, Waltham, Mass) and
monitored for accuracy by TriVascular Inc. An indepen-
dent imaging core laboratory (M2S Inc, West Lebanon,
NH) analyzed all preoperative and postoperative CT scans
and radiographs. A CEC reviewed and adjudicated all
device-related adverse events and SAEs and classiﬁedMAEs. Adverse events were categorized using the Medical
Dictionary for Regulatory Activities. An independent Data
and Safety Monitoring Board (Axio Research Acquisition
Co, LLC, Seattle, Wash) regularly monitored the progress
of the trial.
Hypotheses. The primary safety hypothesis was tested
by comparing the 30-day incidence of MAEs in patients
treated with the Ovation stent graft to a predeﬁned target
performance goal of 21%. The primary effectiveness
hypothesis was tested by comparing the 1-year composite
treatment success rate in patients treated with the Ovation
stent graft to a predeﬁned target performance goal of 80%.
Statistical analysis. Statistical tests for main study
outcomes were prespeciﬁed in a statistical analysis plan.
Continuous variables are reported as mean 6 standard
deviation or median, depending on normality assumptions.
Categoric variables are presented as number (%). The safety
and effectiveness hypotheses were each tested by calcu-
lating a one-sided 95% conﬁdence limit using the Wilson
method18 and then comparing with the target performance
goal. All safety outcomes that identiﬁed #365 days of
endovascular AAA treatment were included in the analysis.
Table I. Baseline patient characteristics
Characteristic Valuesa
Age, years 73 6 8
Male gender 88 (141/161)
ASA classiﬁcation
I 6 (9/161)
II 28 (45/161)
III 60 (96/161)
IV 7 (11/161)
Medical historyb
Hypertension 85 (136/161)
Hyperlipidemia 70 (113/161)
Smoking 70 (113/161)
Coronary artery disease 45 (72/161)
Chronic obstructive pulmonary disease 27 (44/161)
Peripheral vascular disease 24 (38/161)
Arrhythmia 22 (35/161)
Diabetes mellitus 21 (34/161)
Myocardial infarction 21 (33/161)
Renal failure/insufﬁciency 14 (22/161)
Carotid artery disease 13 (21/161)
Valvular heart disease 12 (19/161)
Aortoiliac morphology
Proximal neck length, mm 23 6 13
Juxtarenal angle,  19 6 14
Maximum aneurysm diameter, mm 54 6 9
Left common iliac diameter, mm 13.7 6 3.3
Left minimum iliac access diameter, mm 7.0 6 1.6
Right common iliac diameter, mm 13.9 6 3.0
Right minimum iliac access diameter, mm 7.0 6 1.6
ASA, American Society of Anesthesiologists.
aValues are presented as percentage (n/N) or mean 6 standard deviation.
bConditions listed with frequency $10%.
Table II. Procedural details
Characteristic Valuesa
Access
Delivery success 100 (161/161)
Vascular access
Cutdown 52 (84/161)
Percutaneous 43 (69/161)
Percutaneous and cutdown 5 (8/161)
Procedure
Deployment success 100 (161/161)
Anesthesia typeb
General 66 (106/161)
Local 24 (38/161)
Regional 17 (27/161)
Conscious sedation 11 (18/161)
Procedure time, minutes 110 6 41
Procedural blood loss, mLc 150
Hospital length of stay, daysc 1
Devices
Aortic body diameter
20 mm 3 (4/161)
23 mm 22 (35/161)
26 mm 36 (58/161)
29 mm 28 (45/161)
34 mm 12 (19/161)
Iliac limb diameter
10 mm 6 (20/366)
12 mm 22 (80/366)
14 mm 35 (128/366)
16 mm 17 (62/366)
18 mm 14 (52/366)
22 mm 7 (24/366)
aValues are presented as percentage (n/N) or mean 6 standard deviation,
unless otherwise noted.
bNumerator >161 due to multiple methods used in some patients.
cMedian.
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visit, which conservatively included images taken through
18 months to account for late follow-up visits, were
analyzed and included in this report. Patients with readable
imaging during each respective follow-up interval were
included in the denominator for relevant effectiveness end
points. Data were analyzed by an independent statistician
using SAS 9.2 software (SAS Institute Inc, Cary, NC).
Details regarding the patient inclusion and exclusion
criteria, procedure details, and all investigators and sites
are presented in the Supplementary materials (available
online).
RESULTS
Patient accountability. A total of 92 screened patients
were deemed ineligible for participation in the study based
on inclusion or exclusion criteria. The most common
causes of screening failures were presence of signiﬁcant
aortic neck angulation, aortic neck length of <7 mm, and
aortic neck diameter of <16 mm or >30 mm. A total of
161 patients who met eligibility criteria were enrolled
and underwent EVAR with the Ovation stent graft. Enroll-
ment included 111 patients from 28 sites in the U.S., 30
patients from seven sites in Germany, and 20 patients
from one site in Chile. Through 1 year, four patients
died, four patients withdrew, and one patient was lost tofollow-up. Complete 1-year follow-up data were available
for all other patients.
Baseline characteristics. Baseline patient characteris-
tics are presented in Table I. Of the 161 study partici-
pants, 141 (88%) were men, mean age was 73 years
(range, 54-95 years), and mean maximal AAA diameter
was 5.4 cm. Comorbidities included hypertension (85%),
hyperlipidemia (70%), smoking (70%), coronary artery
disease (45%), chronic obstructive pulmonary disease
(27%), peripheral vascular disease (24%), diabetes mellitus
(21%), and chronic renal insufﬁciency (14%). During this
study, aortoiliac morphology was present in 39% of
patients that fell outside of the indications for use of any
currently FDA-approved stent grafts available in the U.S.,
including 25 patients with proximal aortic neck
length <10 mm and 50 patients with minimum access
vessel diameter of <6 mm. Twelve patients presented with
both proximal aortic neck length of <10 mm and
minimum access vessel diameter of <6 mm. The inclusion
criteria included patients with maximum AAA diameter
that was >1.5 times the transverse dimensions of an
adjacent nonaneurysmal aorta; three patients in the study
met this criterion and had maximum AAA diameters of
between 3.8 and 4.0 cm.
Fig 4. Kaplan-Meier curve shows freedom from major adverse events (MAEs) through 1 year.
JOURNAL OF VASCULAR SURGERY
70 Mehta et al January 2014Procedural data. Successful arterial access and device
deployment was achieved in all patients (Table II).
Totally percutaneous access was used in 69 patients (43%).
The mean procedural-related blood loss was 150 mL, and
the median hospitalization was 1 day.
Safety outcomes. The 30-day MAE rate, the primary
safety end point of the study, was 3%, with an upper-bound
95% conﬁdence interval of 5%. The 30-day MAE rate was
signiﬁcantly lower than the 21% target performance goal.
The MAE rate through 1 year was 6% (Fig 4). There were
no device-related MAEs based on CEC-adjudicated data
through 1 year. AAA-related mortality through 1 year was
1%. All-cause mortality through 1 year was 3%. Causes of
death included disseminated intravascular coagulation and
abdominal sepsis (day 17), respiratory failure (day 95),
multiple organ failure (day 178), and suspected thor-
acoabdominal aneurysm rupture (day 359; Table III).
The one 30-day death occurred in a 76-year-old
patient in whom an unanticipated adverse device effect
occurred, which was reported to the FDA. During the
procedure, the ﬁll tube that injects the ﬁll material into
the aortic body stent graft had become disconnected, and
the ﬁll material was injected intravascularly. The patient
showed signs of anaphylactoid response during the proce-
dure and was treated and stabilized before the EVAR
procedure was completed, with adequate aneurysm exclu-
sion. The patient was subsequently transferred to the inten-
sive care unit and treated for multisystem organ failure. On
postoperative day 16, patient returned to the operating
room and underwent subtotal colectomy for a perforated
bowel. The following day, patient died of multisystem
organ failure and disseminated intravascular coagulopathy.A thorough root cause analysis was launched, and the
evaluation identiﬁed a defective molded polycarbonate
component (distal stop) that allowed the port for the ﬁll
material to prematurely disconnect from the aortic stent
graft main body catheter. The distal stop provides a compo-
nent “lock” to maintain connection of the ﬁll port to the
ﬁll tube during ﬁll material injection. Investigation of the
delivery catheter conﬁrmed that this component was frac-
tured, which could have led to less force required to inad-
vertently disconnect the ﬁll tube. TriVascular worked with
the FDA in taking appropriate steps to modify the distal
stop, which then was tested by simulated use to verify
the modiﬁcations met the speciﬁcations and requirements.
Furthermore, protocol, informed consent, and instructions
for use modiﬁcations were implemented, including the
exclusion criteria of a known allergy to polyethylene
glycol-based polymers, before the trial was continued.
Effectiveness outcomes. The 1-year treatment success
rate, the primary effectiveness end point of the study, was
99% with a lower-bound 95% conﬁdence interval of 97%.
All patients were followed up for a minimum of 1 year. The
1-year treatment success rate was signiﬁcantly higher than
the 80% target performance goal. The imaging core labo-
ratory reported no type I, III, or IV endoleaks or stent graft
migration. AAA enlargement was identiﬁed by the imaging
core laboratory in one patient (1%) at the 1-year follow-up
(Table IV), but the site reported no AAA enlargement.
Type II endoleak was identiﬁed in 49 patients (34%) at
1 year. Site-reported type I endoleaks were identiﬁed in
three patients (2%), but the core laboratory did not identify
any of these endoleaks as type I. Stent fractures were
identiﬁed in four patients (3%) at 1 year, none of which
Table III. Safety outcomes through 1 year
Outcome
30 days %
(n/N)
1 year %
(n/N)
Death 0.6 (1/161) 3 (4/161)
SAEsa 13 (21/161) 39 (62/161)
Injury, poisoning, and
procedural complications
4 (6/161) 9 (15/161)
Respiratory, thoracic, and
mediastinal disorders
3 (5/161) 8 (13/161)
Vascular disorders 3 (4/161) 7 (11/161)
Cardiac disorders 2 (3/161) 7 (11/161)
Gastrointestinal disorders 2 (3/161) 7 (11/161)
Neoplasms 0% 6 (10/161)
General disorders and
administration site
conditions
4 (6/161) 6 (9/161)
Infections and infestations 0.6 (1/161) 5 (8/161)
MAEs 2.5 (4/161) 6 (10/161)
Myocardial infarction 1 (2/161) 3 (4/161)
Procedural blood loss
$1000 mL
1 (2/161) 1 (2/161)
Renal failure 1 (2/161) 1 (2/161)
Bowel ischemia 0.6 (1/161) 1 (2/161)
Death 0.6 (1/161) 3 (4/161)
Respiratory failure 0.6 (1/161) 1 (2/161)
Stroke 0 0
Paraplegia 0 0
MAEs, Major adverse events; SAEs, serious adverse events.
aSAEs were categorized by System Organ Class using the Medical Dictio-
nary for Regulatory Activities.
Table IV. Effectiveness outcomes through 1 year
Outcome
30 days %
(n/N)
1 year %
(n/N)
Radiographic eventsa
Endoleak 44 (68/153) 39 (55/143)
Type I 0 (0/153) 0 (0/143)
Type II 41 (62/153) 34 (49/143)
Type III 0 (0/153) 0 (0/143)
Type IV 0 (0/153) 0 (0/143)
Indeterminate origin 4 (6/153) 4 (6/143)
Stent graft migrationb NA 0 (0/150)
AAA diameter changeb
$5 mm increase NA 0.7 (1/150)
<5 mm change NA 67 (101/150)
$5 mm decrease NA 32 (48/150)
Stent fracture 0.6 (1/157) 3 (4/146)
Clinical eventsc
Access failure 0 (0/161) NA
Deployment failure 0 (0/161) NA
AAA rupture 0 (0/161) 0 (0/161)
Conversion to open surgery 0 (0/161) 0 (0/161)
AAA-related secondary
intervention
1 (2/161) 6 (10/161)
AAA, Abdominal aortic aneurysm; NA, not applicable.
aPatients with readable imaging assessed by the core laboratory were
included in the denominator for each respective outcome.
bCompared with 1-month baseline image.
cSite reported through 1 year.
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treatment. No AAA ruptures or conversion to open
surgical repair have occurred. AAA-related secondary
procedures were performed in 10 patients (6%) for 12
ﬁndings, including type I endoleaks (three), type II
endoleaks (three), aortic main body stenosis (three), and
iliac limb stenosis or occlusion (three). One patient
underwent a secondary procedure to resolve two ﬁndings
(type Ia endoleak and aortic main body stenosis). In
a second patient, two secondary procedures were per-
formed, one to resolve a type Ia endoleak and another to
resolve a type Ib endoleak (Table V).
Post hoc analyses. Post hoc exploratory analyses of the
primary study end points and AAA-related secondary
procedures were conducted based on the presence or
absence of challenging aortoiliac anatomy and based on
access method. Challenging aortoiliac anatomy was deﬁned
as at least one access vessel of <6 mm in diameter or prox-
imal neck length of <10 mm, or both, based on the imaging
core laboratory measurement. Overall, 63 of 161 patients
(39%) met these criteria. Of these, 39 (24%) had maximum
iliac diameter of <6 mm only, 13 (8%) had an aortic neck
length of <10 mm, and 11 (7%) had an iliac diameter
of <6 mm and an aortic neck length of <10 mm. Of the 50
patients with iliac diameter <6 mm, 14 (28%) were women.
MAE rates through 30 days were comparable (P ¼ .16)
in patients with challenging anatomy (0% [zero of 63])
compared with those with typical anatomy (4% [four of
98]). All patients with challenging anatomy achievedtreatment success. AAA-related secondary procedures
were comparable and performed in 3% (two of 63) of
patients with challenging anatomy compared with 8%
(eight of 98) of those with typical anatomy (P ¼ .32).
Access was achieved by cutdown in 92 patients (57%)
and was totally percutaneous in 69 (43%). Overall, clinical
outcomes in these subgroups were comparable, including
MAE (5.4% vs 7.2%) and treatment success (99% vs
100%), for cutdown and percutaneous access, respectively,
with a slight advantage with percutaneous access for
shorter anesthesia time (191 vs 149 minutes), shorter
procedure time (118 vs 98 minutes), and shorter median
hospitalization (2 vs 1 days). Major blood loss
($1000 mL) occurred in 2.0% (two of 98) of patients
with cutdown. No (zero of 63) major blood loss was
observed in patients with percutaneous access.
DISCUSSION
With the advent of EVAR, stent graft technology has
evolved substantially over the past 2 decades. Most would
agree that based on our current understanding, the ideal
stent graft would go beyond the currently available devices
in having the ability to accommodate the aortic neck for
seal and provide ﬁxation that can withstand the aortic
forces and prevent migration and endoleaks. It would
also have the ability for controlled, accurate positioning
and deployment, and a low proﬁle that could navigate
through access vessels with signiﬁcant tortuosity and calci-
ﬁcations and reduce device-related complications.
The Ovation stent graft is characterized by a trimodular
design, with the aortic body composed of a low-permeability
Table V. Abdominal aortic aneurysm (AAA)-related
secondary procedures through 1 year
Outcome
30 days %
(n/N)
1 year %
(n/N)
AAA-related secondary
procedurea
1 (2/161) 6 (10/161)
Aortic body stenosis 0.0 (0/161) 2 (3/161)
Iliac limb occlusion 0.6 (1/161) 1 (2/161)
Iliac limb stenosis 0.6 (1/161) 0.6 (1/161)
Type Ia endoleak 0.0 (0/161) 1 (2/161)
Type Ib endoleak 0.0 (0/161) 0.6 (1/161)
Type II endoleak 0.0 (0/161) 2 (3/161)
aTwo patients had one intervention to treat two outcomes.
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provide active ﬁxation. Unlike the previous stent grafts, the
Ovation aortic body contains a network of inﬂatable sealing
rings and channels that are ﬁlled with a low-viscosity radi-
opaque polymer during stent graft deployment. As the
polymer cures in situ, it conforms to aortic necks of various
shapes and provides proximal stent graft seal. The Ovation
main body is delivered through a ﬂexible hydrophilic-
coated 14F OD catheter, the smallest proﬁle of any
currently commercially available stent graft. The Ovation
iliac limbs are composed of highly ﬂexible nitinol stents
encapsulated in low-permeability PTFE that are packaged
in low-proﬁle 13F to 14F OD delivery systems that allow
access in iliac arteries as small as 4.7 mm.
With these design characteristics, during the pivotal
trial, the Ovation stent graft was implanted successfully in
100% of patients, and nearly 50% were treated percutane-
ously, without any access failures, type I or III endoleaks,
stent graft migration, explant, or aneurysm rupture.
Furthermore, at 1 year, the primary effectiveness end point
of the study was achieved in 99% of the patients, with
limited MAEs.
EVAR with the Ovation stent graft results in favorable
outcomes compared with open surgery. The 1-year results
of this study suggest favorable outcomes vs those reported
for open surgery for several key variables,7 including all-
cause mortality (3% vs 8%), AAA-related mortality (0.6%
vs 3%), and, most notably, MAEs (6% vs 58%). These
results with the Ovation stent graft also compare favorably
with results of currently marketed stent grafts. In addition
to 100% technical success, 1-year outcomes included only
a 0.6% AAA-related mortality rate and a 0.6% AAA enlarge-
ment rate. With currently marketed stent grafts, technical
success ranged from 97% to 100%, 1-year AAA-related
mortality rate was 0% to 2%, and 1-year complication rates
were 0% to 3% for type I endoleak, 0% to 7% for AAA
enlargement, 0% to 2% for device migration, 0% to 1%
for AAA rupture, and 0% to 2% for conversion to
surgery.19-23 The results of the current study also indicate
that 39% of patients presented with aortoiliac anatomy
that would be difﬁcult to treat with currently available stent
grafts.24,25 Furthermore, safety and effectiveness outcomeswere equally favorable in patients with typical or chal-
lenging anatomy.
One of the most common reasons for EVAR ineligi-
bility is related to access. The Ovation stent graft accom-
modates access in w90% of men and 70% of women with
AAA, based on data from the Characterization of Human
Aortic Anatomy Project.26 In comparison, the minimum
iliac diameter that can be accommodated with many other
stent grafts is 6 mm, which allows access in only w70% of
men and 40% of women. Even in patients with challenging
anatomy, the Ovation stent graft yielded excellent results,
including 100% technical success, 97% freedom from
MAEs through 1 year, and 3.2% freedom from MAEs
with AAA-related secondary procedures. The Ovation stent
graft has the ability to treat a wider range of patients
compared with other stent grafts, especially those with
narrow access vessels and short proximal necks, without
sacriﬁcing patient safety or device effectiveness.
Type II endoleaks were identiﬁed in 34% of patients at
the 1-year follow-up visit. This endoleak rate, although
higher than anticipated, is within the typically reported
range27 and may be partly due to the stringent CT protocol
that recommended a maximum slice thickness of 2 mm.
The median type II endoleak volume at 1 year was only
1 mL. For comparison, the mean volume of type II endo-
leaks that undergo intervention is 7 mL, whereas those that
require no intervention average 4 mL.28 Given the positive
relationship between endoleak volume and aneurysm wall
pressure,29 these small type II endoleaks may portend
a benign clinical course. The long-term trajectory of these
endoleaks will be monitored and remains to be determined
as patients undergo regular surveillance annually for 5 years
under the study protocol.
The strengths of this trial included a large sample size,
excellent generalizability attributable to enrollment at 36
sites in three countries, and stringent data collection, moni-
toring, and review methods following a common prospec-
tive protocol.
This study also had several limitations worth noting.
First, this was a noncontrolled study, and therefore,
comparative performance of the Ovation stent graft with
alternative AAA treatments cannot be directly evaluated.
Second, that women comprised 20 of 161 enrolled patients
(12%) and that the mean maximum aneurysm diameter was
5.4 cm may be viewed as a limitation and may have biased
the results in a favorable manner. A ﬁnal study limitation is
that the durability of the Ovation stent graft is not yet
established beyond 1 year. Additional study will be
required to elucidate long-term outcomes.
CONCLUSIONS
The 1-year outcomes with the Ovation stent graft
are promising, with excellent demonstrated safety and
effectiveness in patients with AAA. These results were simi-
larly remarkable in patients with challenging anatomic
characteristics who would be ineligible for treatment
with other approved stent grafts. The Ovation stent graft
may help to expand the patient population eligible for
JOURNAL OF VASCULAR SURGERY
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of aortoiliac anatomies.
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Ovation endovascular aneurysm repair (EVAR)
Procedural details. The endovascular procedures were
performed in a dedicated surgical-angiography suite.
Patients were routinely heparinized before the procedure.
The Ovation stent graft was inserted using a bilateral trans-
femoral approach in all cases. The ﬁrst step consisted of
bilateral positioning of a 0.035-inch guidewire for the
insertion of two 8F short introducer sheaths. A 5F pigtail
catheter was then positioned immediately above the renal
artery ostia, and intraoperative angiography was performed.
The stent graft delivery system was advanced contralat-
erally with the support of a 180-cm Amplatz stiff guidewire
(Cook Medical, Bloomington, Ind). A craniocaudal projec-
tion was performed to identify the proximal radiopaque
markers in the landing zone. The aortic body was then
deployed using stent release knobs on the handle.The ﬁll polymer was mixed inside a dedicated kit by
alternately depressing the two-syringe plunger for approx-
imately 15 strokes. Next, the full syringe was connected
to the ﬁll polymer injection port on the catheter handle
and the syringe plunger was injected into an auto injector
that warmed and applied controlled pressure to the poly-
mer to ﬁll the ring network. After the ﬁll polymer solidi-
ﬁed within the sealing rings, the aortic body delivery
catheter was disengaged from the ﬁll polymer injection
port and withdrawn from the vasculature.
The contralateral and ipsilateral iliac limbs were each
deployed through iliac limb delivery catheters. A 180-cm
Amplatz stiff wire was passed from the contralateral access
site into the contralateral distal leg of the aortic body. The
contralateral iliac limb was then advanced into position and
deployed. The ipsilateral iliac limb delivery catheter was
advanced over the guidewire and deployed.
After the procedure, anticoagulation was routinely
antagonized with protamine sulfate.
Supplementary Table I (online only). Enrolling principal investigators and institutions in the Ovation United States
(U.S.) Food and Drug Administration (FDA)-investigational device exemption study sorted in descending order of
patient enrollment by country and, secondarily, by site
Investigator Institution
U.S.
Manish Mehta The Vascular Group, PLLC, Albany, NY
Gregory Mishkel Prairie Education and Research, Springﬁeld, Ill
William Jordan University of Alabama-Birmingham, Birmingham, Ala
Charles Botti Riverside Methodist Hospital, Columbus, Ohio
Mark Eskandari Northwestern Memorial Hospital, Chicago, Ill
Bruce Gray Greenville Hospital System, Greenville, SC
Karthik Kasirajan Emory University Hospital, Atlanta, Ga
Daniel Clair Cleveland Clinic Foundation, Cleveland, Ohio
Adnan Rizvi Abbott Northwestern Hospital, Minneapolis, Minn
Mohiuddin Cheema Hartford Hospital, Hartford, Conn
John Henretta Mission Hospital, Asheville, NC
Wesley S. Moore UCLA Medical Center, Los Angeles, Calif
Stephen Motew Forsythe Medical Center, Winston-Salem, NC
John Eidt Central Arkansas Veterans Healthcare System, Little Rock, Ark
Brijeshwar Maini Mofﬁtt Heart Pinnacle Health, Wormsleyburg, Pa
Dipankar Mukherjee INOVA Fairfax Hospital, Falls Church, Va
Charles Sternbergh Ochsner Health Systems, New Orleans, La
Kim Hodgson Southern Illinois University, Springﬁeld, Ill
Ash Jain Washington Hospital, Fremont, Calif
Douglas Jicha Santa Rosa Memorial Hospital, Santa Rosa, Calif
Paul Jones Mercy Hospital and Medical Center, Chicago, Ill
Heitham Hassoun Methodist Hospital, Houston, Tex
Thomas Maldonado NYU Hospitals Center, New York, NY
Marc H. Glickman Vascular and Transplant Specialists, Norfolk, Va
Paul Haser University of Medicine and Dentistry of New Jersey, Stratford, NJ
Zvonimir Krajcer St. Luke’s Episcopal Hospital, Houston, Tex
John Laird UC Davis Vascular Center, Sacramento, Calif
Michel Makaroun UPMC Shadyside Hospital, Pittsburgh, Pa
Germany
Thomas Nolte Herz- und Gefässzentrum, Bad Bevensen
Hans Krankenberg Univiersitäres Herz und Gefaßzentrum, Hamburg
Horst Sievert Cardiovascular Center Frankfurt-Sankt Katherine, Frankfurt
Klaus Mathias Klinikum Dortmund GmbH, Dortmund
Dierk Scheinert Herzzentrum Leipzig, Leipzig
Giovanni Torsello Sankt Franziskus Hospital, Münster
Jan Brunkwall University Klinik Koln, Koln
Chile
Francisco Valdés Pontiﬁcia Universidad Catolica de Chile, Santiago
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Supplementary Table II (online only). Inclusion and exclusion criteria for the Ovation United States (U.S.) Food and
Drug Administration (FDA)-investigational device exemption study
Inclusion criteria
Age $18 years
Male or nonpregnant female
Patient has signed an Ethics Committee/Institutional Review Board-approved informed consent form
Candidate for open surgery
Infrarenal AAA
(1) $5.0 cm in diameter,
(2) has increased in diameter by at least 0.5 cm in last 6 months, or
(3) maximum diameter >1.5 times that of adjacent nonaneurysmal segment
Patent iliac or femoral arteries that allow endovascular access with the TriVascular AAA device
Suitable nonaneurysmal proximal aortic neck length of $7 mm inferior to the most distal renal artery ostium
Suitable nonaneurysmal distal iliac artery length (seal zone) of $10 mm with repair anticipated to preserve at least one hypogastric artery
Suitable nonaneurysmal proximal aortic neck luminal diameter between 16 and 30 mm
Suitable nonaneurysmal distal iliac luminal diameters between 8 and 20 mm
Distance from the most distal renal artery to most superior internal iliac artery measurement $13 cm
Juxtarenal aortic neck angulation #60 if proximal neck length is $10 mm or #45 if proximal neck length is <10 mm
Willing to comply with all required follow-up examinations
Exclusion criteria
Dissecting or acutely ruptured aneurysm
Concomitant thoracic aneurysm or dissection
Acute vascular injury
Need for emergent surgery
Mycotic aneurysm or active systemic infection
Unstable angina
Myocardial infarction or stroke in the past 6 months
Major surgical or interventional procedure planned #30 days of the AAA procedure
Connective tissue disease (eg, Marfan or Ehlers-Danlos syndrome)
Bleeding disorder or history of refusing blood transfusions
Dialysis-dependent renal failure or baseline serum creatinine level >2.0 mg/dL
Hypersensitivity or contraindication to anticoagulation or contrast media
Allergy or intolerance to PTFE, polyethylene glycol-based polymers, ﬂuorinated ethylene propylene, or nitinol
Body habitus hinders radiographic visualization of the aorta
Life expectancy <1 year
Participation in another investigational device or drug clinical trial
Medical, social, or psychological conditions that, in the opinion of the investigator, preclude patient from receiving the required
procedures and evaluations
AAA, Abdominal aortic aneurysm; PTFE, polytetraﬂuoroethylene.
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